# Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 Virus

> **NCT04355052** · PHASE3 · UNKNOWN · sponsor: **Sheba Medical Center** · enrollment: 250 (estimated)

## Conditions studied

- COVID - 19

## Interventions

- **DRUG:** hydroxychloroquine in combination with camostat mesylate
- **DRUG:** Hydroxychloroquine in combination of Azithromycin

## Key facts

- **NCT ID:** NCT04355052
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-11
- **Primary completion:** 2020-10-11
- **Final completion:** 2020-12-11
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2020-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04355052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04355052, "Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 Virus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04355052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*